Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Merck
Healthtrust
Mallinckrodt
Moodys
Federal Trade Commission
Daiichi Sankyo
Accenture
Johnson and Johnson

Generated: April 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,897,646

« Back to Dashboard

Which drugs does patent 7,897,646 protect, and when does it expire?

Patent 7,897,646 protects SYMBICORT and is included in one NDA.

Protection for SYMBICORT has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has forty-four patent family members in thirty-five countries.
Summary for Patent: 7,897,646
Title:Use for budesonide and formoterol
Abstract:The invention provides the use of formoterol and budesonide in the treatment of chronic obstructive pulmonary disease.
Inventor(s): Bauer; Carl-Axel (Lund, SE), Trofast; Jan (Lund, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/010,283
Patent Claim Types:
see list of patent claims
Use; Composition; Delivery;

Drugs Protected by US Patent 7,897,646

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca SYMBICORT budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 021929-002 Jul 21, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,897,646

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9703407-8Sep 19, 1997

Non-Orange Book US Patents Family Members for Patent 7,897,646

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,006,189,587 ➤ Try a Free Trial
8,461,211 Use for budesonide and formoterol ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 7,897,646

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Czech Republic 295250 ➤ Try a Free Trial
European Patent Office 1210943 ➤ Try a Free Trial
Germany 69834955 ➤ Try a Free Trial
Denmark 1014993 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Accenture
UBS
McKinsey
Johnson and Johnson
Covington
Merck
Queensland Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.